President's Message
Dear Colleagues,
Can you feel the excitement in the air? SITC 2013 is a little over a month away! If you have not registered yet, early registration rates are available for only a few more days – until Sunday, October 6, 2013 at 11:59 pm PST. I encourage you to register today and save substantially over the regular and onsite registration rates.
To add to the excitement, the schedule has been announced for SITC's Hot Topic Symposium on Predictive Biomarkers in Checkpoint Blockade: Is PD-L1 Tumor Expression Necessary? SITC 2013 is your opportunity to join basic researchers, clinicians, students, postdoctoral fellows, and allied health professionals from around the world for a week of networking, collaboration and scientific exchange on some most of the important issues in our field today.
Along with the upcoming Annual Meeting & Associated Programs, SITC is also collaborating with several domestic and global institutions and organizations for additional educational programs through the end of 2013 and into 2014. From our U.S.-based, regional “Advances in Cancer Immunotherapy" programs, to programs in Italy, Germany and Qatar, SITC continues to drive the field forward through education and collaboration. You can find more detailed information on all these programs below.
Through all of these upcoming programs, SITC is looking forward to some very exciting times filled with the most innovative science, education and collaboration in the field. On behalf of the Society, I hope you’ll join us along the way.
Sincerely,
.jpg){kind=small}
Francesco Marincola, MD
SITC President
Order Your SITC Friend of the Society Ribbons
SITC members can show their support for the Society, SITC's Forward Fund and their commitment to the field by purchasing a “Friend of the Society” ribbon when registering online for SITC 2013. Ribbons can also be purchased in person at the SITC registration desk over the course of the meeting. “Friend of the Society” ribbons are designed to be worn on the name badges of delegates attending and can be acquired for a minimum donation of $50. Ribbons can be purchased personally or for distribution to other recipients.
As a 501(c)(3) organization, donations made to SITC are tax deductible as charitable contributions to the extent allowed by law.
Schedule Announced!
SITC Hot Topic Symposium on Predictive Biomarkers in Checkpoint Blockade: Is PD-L1 Tumor Expression Necessary?
(As of 10/2/13 - subject to change)
- Introduction
Jedd D. Wolchok, MD, PhD - Memorial Sloan-Kettering Cancer Center - Genentech Data
Omid Hamid, MD - The Angeles Clinic and Research Institute
- Bristol-Myers-Squibb Data
Margaret K. Callahan, MD, PhD - Memorial Sloan-Kettering Cancer Center
Janis Taube, MD - Johns Hopkins School of Medicine
- Updates on PD-L1 Assays: Bristol-Myers-Squibb
Joseph Grosso, PhD - Bristol-Myers-Squibb
- Updates on PD-L1 Assays: Merck
TBD - Updates on PD-L1 Assays: Academia
TBD - Updates on PD-L1 Assays: Genentech
Ira Mellman, PhD - Genentech - Panel Discussion - Predictive Biomarkers in the Checkpoint Blockade: Is PD-L1 Tumor Expression Necessary?
Margaret K. Callahan, MD, PhD - Memorial Sloan-Kettering Cancer Center
Joseph Grosso, PhD - Bristol-Myers-Squibb
Omid Hamid, MD - The Angeles Clinic and Research Institute
Ramy Ibrahim, MD - MedImmune
Mario Sznol, MD - Yale University School of Medicine
Janis Taube, MD - Johns Hopkins School of Medicine
For more information visit: www.sitcancer.org/2013/hot-topic-symposium.
Registration Open for all "Advances in Cancer Immunotherapy" Regional Programs
 |
Specifically designed for clinical oncologists and the entire unit of care involved in treating cancer patients with immunotherapy, these CME-certified programs provide an understanding of basic immunology principles underlying the clinical application of immunotherapy, provide insights into the indications and clinical management of patients receiving tumor immunotherapy, and discuss emerging drugs and concepts in the tumor immunotherapy field.
These programs will also summarize central themes in research advances and approvals to:
- Facilitate understanding of more sophisticated principles of tumor immunology and immunotherapy
- Promote appropriate clinical application of cancer immunotherpies, how they work, their side effects and efficacy to improve cancer patient outcomes
For more information and to register for any of these programs, visit: www.sitcancer.org/sitc-meetings/aci2013.
SITC Partners with KCA and Hosts Cancer Immunotherapy Session at 12th International Kidney Cancer Symposium
Saturday, October 26, 2013 • 10:05 am - 11:55 am • Radisson Blu Aqua Hotel • Chicago, IL
Directed toward medical oncologists, urologists and scientists involved in the clinical and research aspects of renal cell carcinoma, this meeting is sponsored by the Kidney Cancer Association (KCA) and SITC to provide a forum for the exchange of ideas and information that will continue to frame directions for future research and treatment.
For more information visit: www.sitcancer.org/sitc-meetings/kca2013.
New International Program Announced!
Updates on Immunotherapy of Cancer and Immunoscore
Part of the Sidra Symposia Series, Held in Partnership with the Society for Immunotherapy of Cancer
January 22-23, 2014 • St. Regis Doha • Doha, Qatar
This symposium in partnership with Sidra Medical and Research Center, provides an educational environment focused on improving the outcome for patients with cancer by incorporating strategies based on cancer immunotherapy. With leading authorities in tumor immunology and cancer immunotherapy, as well as oral abstract and poster presenters, this program will describe the latest research advances, focus on currently approved and emerging tumor immunotherapy approaches, provide highlights on SITC initiatives and projects and offer updates on international initiatives, including the Immunoscore.
More information on registration, abstract submission and award opportunities is coming soon! For updates, please visit: www.sitcancer.org/sitc-meetings/sidrasymposium.
SITC Continues Partnership at Melanoma Bridge 2013
December 5-8, 2013 • Royal Continental Hotel • Naples, Italy
Melanoma Bridge 2013 is jointly organized by SITC, Istituto Nazionale Tumori Fondazione "G. Pascale,” Sidra Medical and Research Center, and Fondazione Melanoma Onlus and aims to achieve a broad-based participation by various groups and societies sharing a clinical or basic interest in the immunology and biology of the cancer microenvironment. The meeting will consist of the following sections:
|
|
For more information visit: www.sitcancer.org/sitc-meetings/melanoma-bridge-2013.
SITC Joins BDA and Others for 1st European Immunotherapy of Cancer Conference
March 12-14, 2014 • Munich, Germany
As the first European Cancer Immunotherapy meeting, the goal of this conference is to provide a forum for discussion on early clinical drug development and address the unique challenges involved. The program will focus on topics such as immunomodulatory agents, anti-cancer vaccines and monoclonal antibodies with special emphasis on translational research and biomarker development. Organized by the Biotherapy Development Association (BDA), partners include SITC, Comprehensive Cancer Center of the Ludwig-Maximilians-Universitat Munchen (CCCLMU), Roman-Herzog-Krebszentrum Comprehensive Cancer Center (RHCCC) and Munich Tumor Center (TZM).
Early registration deadline is October 8! For more information, to submit an abstract and to register, visit: www.ecco-org.eu/Events/ITOC1/Registration.aspx.
Advertisement
